Seminars in Oncology Nursing
Volume 23, Issue 1 , Pages 29-36 , February 2007

Managing High-Risk Breast Cancer

  • Frances M. Palmieri

      Affiliations

    • Corresponding Author InformationAddress correspondence to Frances M. Palmieri, RN, MSN, OCN©, Breast Clinic and Breast Cancer Program, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224
    • ,
  • Edith A. Perez

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Greenberg P, Hortobagyi GN, Smith T, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–2205
  3. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3–27
  4. Tack DK, Palmieri FM, Perez EA. Anthracycline vs nonanthracycline adjuvant therapy for breast cancer. Oncology. 2004;18:1367–1381
  5. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942
  6. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  7. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regime for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  8. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  9. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439
  10. Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199 (abstract # 48). Available at http://www.abstracts2view.com/sabcs05/view.php?nu=SABCS05L_2020. (Accessed Feb 19, 2006).
  11. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658–1667
  12. Albain K, Barlow W, O’Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal ,node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814) (abstract #37). Breast Cancer Res Treat. 2004;88(suppl 1):S20
  13. The National Institutes of Health Consensus Development Conference: Adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr. 2001;November 1-3, 2000. 30:1-152, Bethesda, MD
  14. National Comprehensive Cancer Network. Practice guidelines in oncology: breast cancer v2.2006. Available at http://www.nccn.org. (accessed March 2, 2006).
  15. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467
  16. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: an overview of the randomised trials. Lancet. 1996;348:1189–1196
  17. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802–1810
  18. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  19. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  20. Perez EA, Pusztai L, van De Vijver M. Improving patient care through molecular diagnostics. Semin Oncol. 2004;31(suppl 10):14–20
  21. Perou CM, Sorlie T, Eisen MB, et al. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy generated by cDNA arrays and Affymetrix Gene Chips (abstract 503). Proc Am Soc Clin Oncol. 2004;23:3
  22. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  23. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103–112
  24. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  25. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260–1266
  26. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361–1370
  27. Thomas E, Berner G. Prognostic and predictive implications of HER2 status for breast cancer patients. Eur J Oncol Nurs. 2000;4:10–17
  28. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523–1530
  29. Baselga J, Albanell J, Molina MA, et al. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001;28:4–11
  30. Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253–268
  31. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648
  32. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  33. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  34. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–1878
  35. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  36. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  37. Smith I. Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA Trial): Disease-free and overall survival after 2 year median follow-up. 2006;Presented at the American Society of Clinical Oncology Annual Meeting Scientific Special Session; June 3, 2006; Atlanta, GA
  38. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACÆT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACÆTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. 2006;29th Annual San Antonio Breast Cancer Symposium Oral Presentation, December, 14, 2006, San Antonio, TX
  39. Perez EA, Suman VJ, Davidson NE, et al. Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? (abstract 2038). Breast Cancer Res Treat. 2005;94(suppl 1):S96
  40. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2006; http://www.jco.org/cgi/content/abstract/JCO.2006.09.2775vl
  41. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–7819
  42. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–3038
  43. Williams SA, Schreier AM. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum. 2004;31:E16–E23

PII: S0749-2081(06)00158-6

doi: 10.1016/j.soncn.2006.11.005

Seminars in Oncology Nursing
Volume 23, Issue 1 , Pages 29-36 , February 2007

Article Tools